12 de Octubre tests a cold virus against pancreatic cancer

A trial at Hospital 12 de Octubre uses a modified cold virus that, combined with chemotherapy, extends median survival for metastatic pancreatic cancer patients.

Alberto Sanz
Alberto Sanz
· 2 min read

A clinical trial led by the Hospital 12 de Octubre in Madrid uses a genetically modified cold virus to weaken the barrier protecting the tumour and enhance chemotherapy.

According to Xataka, a clinical trial led by the Hospital 12 de Octubre in Madrid explores a treatment for pancreatic cancer based on a common cold adenovirus, genetically modified to act against the tumour. The Madrid healthcare centre is responsible for the study, the results of which have been published in the journal Nature.

Pancreatic cancer, particularly ductal adenocarcinoma, generates a dense, fibrous extracellular matrix around it that acts as a shield. This barrier makes it difficult for chemotherapy to reach the malignant tissue and limits the action of the body's own defences.

The virus, named VCN-01, was designed by VCN Biosciences, a company based in Barcelona. It has been modified so that it is not destroyed by the liver upon administration, allowing it to circulate in the blood and reach the primary tumour and metastases.

Once inside the cancer cells, the virus replicates to destroy them and produces an enzyme, hyaluronidase, which removes hyaluronic acid from the tumour barrier. This paves the way for chemotherapy.

In the comparative study, patients who received the virus along with chemotherapy achieved a median overall survival of 10.8 months, compared to 8.6 months for those who only received chemotherapy. The difference is at the threshold of what science considers statistically significant, so further trials with more patients will be necessary to confirm the benefit.

The approach has precedents. In 2021, a phase 1 trial led by Marta Bazan-Peregrino demonstrated that direct injection of the virus into the tumour was well tolerated and stabilised the treated lesions. A year later, a phase 1 study led by Dr Rocío García-Carbonero recorded an overall response rate of 50% with intravenous administration and detected viral genetic material in five of the six biopsies analysed.

Trending on the web

Publish an article about your company

An opening, a launch, an award: we publish it as a story, with a permanent URL. Institutions and associations can also send us their statements.

See how →